Analysts Expect The iShares Dow Jones U.S. ETF To Hit $152

&l;p&g;&l;img class=&q;dam-image getty size-large wp-image-1126915586&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/1126915586/960x0.jpg?fit=scale&q; data-height=&q;651&q; data-width=&q;960&q;&g; Getty

Looking at the underlying holdings of the ETFs in our coverage universe at &l;a href=&q;https://www.etfchannel.com/&q; target=&q;_blank&q;&g;ETF Channel&l;/a&g;, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself.&a;nbsp; For the iShares Dow Jones U.S. ETF, we found that the implied analyst target price for the ETF based upon its underlying holdings is $151.70 per unit.

With IYY trading at a recent price near $137.38 per unit, that means that analysts see 10.43% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of IYY&s;s underlying holdings with notable upside to their analyst target prices are Ultragenyx Pharmaceutical, Teladoc Health, and Trinet Group. Although RARE has traded at a recent price of $55.46/share, the average analyst target is 41.39% higher at $78.42/share. Similarly, TDOC has 33.58% upside from the recent share price of $66.58 if the average analyst target price of $88.94/share is reached, and analysts on average are expecting TNET to reach a target price of $59.50/share, which is 20.13% above the recent price of $49.53.

Below is a summary table of the current analyst target prices discussed above:

&l;/p&g;&l;div class=&q;table-wrapper&q;&g;&l;table class=&q;hctblstyle&q; border=&q;0&q; cellspacing=&q;0&q; cellpadding=&q;0&q;&g;&l;tbody&g;&l;tr&g;&l;th&g;Name&l;/th&g; &l;th align=&q;center&q;&g;Symbol&l;/th&g; &l;th align=&q;right&q;&g;Recent Price&l;/th&g; &l;th align=&q;right&q;&g;Avg. Analyst 12-Mo. Target&l;/th&g; &l;th align=&q;right&q;&g;% Upside to Target&l;/th&g; &l;/tr&g;&l;tr&g;&l;td&g;&l;b&g;iShares Dow Jones U.S. ETF&l;/b&g;&l;/td&g; &l;td align=&q;center&q;&g;&l;b&g;IYY&l;/b&g;&l;/td&g; &l;td align=&q;right&q;&g;&l;b&g;$137.38&l;/b&g;&l;/td&g; &l;td align=&q;right&q;&g;&l;b&g;$151.70&l;/b&g;&l;/td&g; &l;td align=&q;right&q;&g;&l;b&g;10.43%&l;/b&g;&l;/td&g; &l;/tr&g;&l;tr&g;&l;td&g;Ultragenyx Pharmaceutical Inc&l;/td&g; &l;td align=&q;center&q;&g;RARE&l;/td&g; &l;td align=&q;right&q;&g;$55.46&l;/td&g; &l;td align=&q;right&q;&g;$78.42&l;/td&g; &l;td align=&q;right&q;&g;41.39%&l;/td&g; &l;/tr&g;&l;tr&g;&l;td&g;Teladoc Health Inc&l;/td&g; &l;td align=&q;center&q;&g;TDOC&l;/td&g; &l;td align=&q;right&q;&g;$66.58&l;/td&g; &l;td align=&q;right&q;&g;$88.94&l;/td&g; &l;td align=&q;right&q;&g;33.58%&l;/td&g; &l;/tr&g;&l;tr&g;&l;td&g;Trinet Group Inc.&l;/td&g; &l;td align=&q;center&q;&g;TNET&l;/td&g; &l;td align=&q;right&q;&g;$49.53&l;/td&g; &l;td align=&q;right&q;&g;$59.50&l;/td&g; &l;td align=&q;right&q;&g;20.13%&l;/td&g; &l;/tr&g;&l;/tbody&g;&l;/table&g;&l;/div&g;

Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock&s;s trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.

&l;a href=&q;http://www.etfchannel.com/slideshows/ten-etfs-with-most-upside/&q; target=&q;_blank&q;&g;Click here to find out 10 ETFs With Most Upside To Analyst Targets &a;raquo;&l;/a&g;